Table 3.
Assessment of symptom severity based on MPN-SAF using a mixed-effects model.
| Symptom | Baseline (n=30), mean (SD) | 12 weeks (n=16), mean (SD) | β coefficient | P value |
| Early satiety | 4.5 (2.9) | 3.8 (3.1) | −0.59 | .21 |
| Abdominal pain | 2.6 (2.5) | 2.8 (2.9) | .10 | .80 |
| Abdominal discomfort | 3.5 (2.8) | 3.6 (3.1) | .01 | .99 |
| Inactivity | 5.2 (2.6) | 3.9 (2.8) | −1.18 | .02 |
| Headaches | 3.6 (3.0) | 2.9 (1.9) | −0.50 | .33 |
| Impaired concentration | 5.2 (3.0) | 3.6 (2.6) | −1.13 | .03 |
| Dizziness | 4.0 (2.8) | 3.1 (2.4) | −1.07 | .02 |
| Numbness | 3.8 (2.6) | 3.0 (2.0) | −0.96 | .02 |
| Insomnia | 5.9 (3.4) | 4.8 (3.1) | −0.53 | .20 |
| Depression | 3.5 (2.6) | 3.2 (2.5) | −0.04 | .93 |
| Sexual dysfunction | 5.2 (3.8) | 3.9 (3.5) | −1.62 | .01 |
| Cough | 1.9 (1.6) | 1.9 (1.9) | −0.23 | .50 |
| Night sweats | 3.7 (2.5) | 2.7 (1.9) | −1.01 | .001 |
| Itching | 3.7 (3.2) | 2.8 (2.7) | −0.05 | .84 |
| Bone pain | 3.3 (2.8) | 2.4 (2.2) | −0.71 | .02 |
| Fever | 1.3 (1.0) | 1.1 (0.2) | .05 | .37 |
| Weight loss | 2.2 (2.5) | 1.4 (0.9) | −0.70 | .10 |
| Quality of life | 5.3 (2.6) | 3.8 (2.2) | −1.27 | .03 |
| MPN-SAFa total score | 68.4 (30.5) | 54.8 (31.6) | −11.19 | .001 |
aMPN-SAF: Myeloproliferative Neoplasm Symptom Assessment Form.